Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

RAY121

Phase 1Small molecule

1

Indications

2

Total Trials

2

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Antiphospholipid Syndrome (APS)Enrolling by invitation

Antiphospholipid Syndrome (APS)Phase 1

Enrolling by invitation

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Antiphospholipid Syndrome (APS)

NCT06371417

Clinical

Trials by Indication[1]

Antiphospholipid Syndrome (APS)2 trials

Phase 1b Open-label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial)

Recruiting· Roche logo

Roche·Phase 1·NCT06371417·144 enrolled

Phase 1b Open-label, Long-term Extension Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW-LTE Trial)

Enrolling by invitation· Roche logo

Roche·Phase 1·NCT06723106·144 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for RAY121. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RAY121 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RAY121. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Roche

Related News